Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042109 (
urticaria
)
6,569
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To study immune responses that may play a role in immediate-type allergic reactions (ITAR) and serum-sickness-like reactions that have been reported with administration of monoclonal antibodies (MAb), we measured by enzyme-linked immunosorbent assay serum levels of IgE, IgG, and IgA human antimurine antibody (HAMA) to T101, a murine IgG2a antibody that has been used in the treatment of
cutaneous T cell lymphoma
(
CTCL
) and chronic lymphocytic leukemia (CLL). None of 8 patients (4 with CLL, 4
CTCL
) pretreated with T101 had elevated titers of any HAMA class tested as compared to normal control sera. All
CTCL
patients who had elevated total serum IgE levels, but normal total serum levels of other antibody classes, had significant rises in IgE, IgG, and IgA HAMA to T101 after intravenous MAb infusion. However, the CLL patients who were hypogammaglobulinemic failed to develop significant rises in HAMA. Three patients (2 CLL, 1
CTCL
) had ITAR (e.g.,
urticaria
, angioedema, bronchospasm) associated with infusion of T101; prophylactic medication regimens based upon the control of radiographic contrast media reactions were used with apparent benefit in subsequent infusions in these patients. All 8 patients had negative immediate intradermal skin tests (1 microgram/ml) to T101 prior to its infusion. Our data confirm that (1) non-IgE-mediated mechanisms cause ITAR from this MAb, possibly by a mechanism inherent in the action of this MAb against lymphocytes, and (2) that isotypic antibody responses to MAb vary with the type of malignancy being treated.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Human IgE, IgG and IgA antibody responses to T101, a murine monoclonal antibody against human lymphocytes: implications for pathogenesis, risk and avoidance of adverse immunologic reactions. 224 27
Pruritus is a natural defence mechanism of the body and creates the scratch reflex as a defensive reaction to potentially dangerous environmental factors. Together with pain, pruritus is a type of superficial sensory experience. Pruritus is a symptom often experienced both in healthy subjects and in those who have symptoms of a disease. In dermatology, pruritus is a frequent symptom associated with a number of dermatoses and is sometimes an auxiliary factor in the diagnostic process. Apart from histamine, the most popular pruritus mediators include tryptase, endothelins, substance P, bradykinin, prostaglandins and acetylcholine. The group of atopic diseases is characterized by the presence of very persistent pruritus. It is found in almost all patients with atopic dermatitis or
urticaria
.
Cutaneous T-cell lymphoma
is another group of pruritic diseases where the symptom of pruritus develops at an early stage and becomes intensified as the disease progresses. Other dermatoses include psoriasis, parasitic diseases and also systemic diseases in which pruritus is often the first and the only symptom suggesting an internal health problem. Cases of pruritus in healthy subjects, possibly associated with skin dryness or pregnancy in women, have also been reported. This paper presents mechanisms responsible for pruritus and the most important dermatoses in which this symptom is found. Treatment of pruritic dermatoses is difficult and always requires an interdisciplinary approach. Not all dermatoses can be successfully treated with antihistamine drugs, particularly if patients suffer from
cutaneous T-cell lymphoma
, liver or kidney diseases. For this reason, the problem of pruritus is the focus of attention of many scientists, and the subject of interdisciplinary studies.
...
PMID:Pruritus in selected dermatoses. 2764 64